Image supplied by WEHI. Calmodulin binds to PSKH1 (in grey) to 'switch on' PSKH1 activity. Reticulocalbin binds to PSKH1 to 'switch off' PSKH1 ...

A new discovery from an international collaborative research team has solved the mystery of how cells turn on their recycling ...

Greatwall, a conserved MAST-like kinase with crucial mitotic entry functions, is curiously absent in worms. Here, the single ...

Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...

The company granted stock options to purchase an aggregate of 208,350 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 272,850 shares of Nurix common ...

The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults ...

Cybersecurity company SailPoint opened for trading on Thursday, returning to the markets more than two years after it went private.Maximize ...

Picture a horse running across an open field, the wind blowing his mane, his hooves stamping into the grassy knoll, eyes on ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...